Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease


News provided by

Resolution Therapeutics

11 Nov, 2024, 08:30 GMT

Share this article

Share toX

Share this article

Share toX

– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis.

– New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages.

– RTX001 has recently entered into a Phase 1/2 interventional study in end-stage liver disease.

EDINBURGH, Scotland and LONDON, Nov. 11, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company spun out of the University of Edinburgh pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases, today announces new clinical and preclinical data highlighting the anti-inflammatory and anti-fibrotic effect of regenerative macrophage therapy. The data will be presented in oral and poster presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024, which is being held in San Diego, California from 15-19 November 2024.

"We believe this strong data reinforces the differentiated potential of regenerative macrophage therapy to meet significant unmet patient needs across the spectrum of inflammatory and fibrotic disease. Based on the clinical data from the MATCH Phase 2 study, and the preclinical data on RTX001, we are confident engineered macrophages can transform patient outcomes in liver cirrhosis and beyond." said Dr Amir Hefni, Chief Executive Officer of Resolution Therapeutics. "With the EMERALD study now open for enrolment and actively recruiting patients, we look forward to generating important clinical data on RTX001 and bringing its therapeutic potential closer to patients in need."

3-year MATCH Phase 2 study demonstrates long-term safety and efficacy with non-engineered macrophages
Data will be presented in an oral presentation titled, "Autologous macrophage therapy decreases major clinical outcomes in patients with compensated cirrhosis: extended data from a randomized controlled Phase 2 trial," by Professor Stuart Forbes. Patients with advanced liver cirrhosis were randomised to triple infusion of macrophages (n = 3), single infusion of macrophages (n = 23) and standard of care (n = 24). Key findings from the data include:

  • Significant reduction in deaths and liver transplants: 3 years after randomisation, 11 patients in the control group experienced 8 deaths and 3 liver transplants collectively, compared to 2 deaths and 0 liver transplants in the treatment groups (Chi-square=7.96, p=0.005).
  • Objective improvement in patient survival: Kaplan Meier analysis demonstrated improved outcomes in overall survival (log-rank test, p=0.018) and transplant-free survival (log-rank test, p=0.002) with macrophage treatment.

Additional clinical insights will be shared during the oral presentation.

Professor Stuart Forbes, Scientific Co-founder of Resolution Therapeutics and Professor of Transplantation & Regenerative Medicine at the University of Edinburgh, said, "We are greatly encouraged by this data which reinforce the longer-term safety and efficacy of macrophage therapy in patients with advanced liver cirrhosis. The significant reduction in clinical events and improved survival observed encourage the further clinical development of novel macrophage therapies with first-in-class potential, like RTX001."

New preclinical data suggest superior anti-inflammatory and anti-fibrotic effect of RTX001 relative to non-engineered macrophages
In a poster presentation titled, "Preclinical proof of concept of safety and efficacy for RTX001, a novel autologous macrophage cell therapy product for end-stage liver disease," Dr Lara Campana will present preclinical proof-of-concept safety and efficacy data for RTX001. Key findings from the data include:

  • Engineering with IL-10 and MMP9 delivers enhanced anti-inflammatory and anti-fibrotic effect: RTX001 showed superior anti-inflammatory and anti-fibrotic effect in vitro versus non-engineered macrophages.
  • Well-tolerated safety profile: In vivo testing of RTX001 showed no safety concerns and a reduction in fibrosis score, further supporting its anti-fibrotic effect.
  • Preclinical profile supportive of clinical development: Preclinical data generated to date on RTX001 provide a rationale to progress the product candidate into clinical evaluation.

Dr Lara Campana, Scientific Co-Founder and Vice President of Research Operations of Resolution Therapeutics, said, "These preclinical data underscore the strength of RTX001's engineering to provide superior anti-inflammatory and anti-fibrotic effect relative to non-engineered macrophages without any compromise to safety. We look forward to deepening our understanding of RTX001 as it enters the clinic and to delivering on the opportunity of macrophage therapy to revolutionise the way inflammatory and fibrotic diseases are treated."

Presentation materials will be made available on the Publications page of the Company's website following the event.

The EMERALD Phase 1/2 interventional study for RTX001 is now recruiting, to investigate the safety and efficacy of RTX001 in patients with ESLD who have recovered from a recent hepatic decompensation.

NOTES TO EDITORS

About RTX001
RTX001 is an engineered, autologous regenerative macrophage therapy with enhanced anti-fibrotic and anti-inflammatory effect. The product candidate is engineered with IL-10-MMP9 mRNA to enhance the natural regenerative properties of macrophages for superior efficacy and durability. RTX001 is being evaluated in the ongoing Phase 1/2 EMERALD study.

About EMERALD
EMERALD is a first-in-human, open-label Phase 1/2 interventional study assessing the safety and efficacy of RTX001 in patients with end-stage liver disease who have recovered from a recent hepatic decompensation. It is conducted in the UK and Spain and began recruiting patients in October 2024. More details on https://resolution-tx.com/patients/ .

About Resolution Therapeutics
Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. The Company leverages its proprietary platform to develop macrophages with pro-regenerative properties for superior patient outcomes. Resolution's initial focus is on developing RTX001, its lead product with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, to treat patients with end-stage liver disease. The Company is also advancing efforts to expand its platform into inflammatory and fibrotic indications beyond liver disease, including graft-vs-host disease (GVHD) and lung fibrosis. Resolution, a spinout from Professor Stuart Forbes's lab at the University of Edinburgh, is based in Edinburgh and London. Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.

About AASLD
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease. It fosters research that leads to improved treatment options for millions of liver disease patients. It advances the science and practice of hepatology through educational conferences, training programs, professional publications, and partnerships with government agencies and sister societies.

Modal title

Also from this source

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage ...

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

Resolution Therapeutics Limited ("Resolution"), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.